Merck (MRK) and Eisai (ESALY) provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating Keytruda plus Lenvima. Merck and Eisai are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma. The decision is based on the recommendation of an independent Data Monitoring Committee, which reviewed data from a planned interim analysis and determined Keytruda plus Lenvima did not demonstrate an improvement in overall survival, one of the study’s dual primary endpoints, versus Keytruda alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Moderna, Merck say mRNA cancer vaccine-KEYTRUDA combo granted PRIME designation
- MRK vs. BMY: Which Pharmaceutical Stock is Better?
- Merck, Proxygen enter collaboration, license agreement
- Padcev combo approval should alleviate concerns on Seagen deal, says BofA
- JPMorgan survey reveals ‘underappreciated pipeline opportunity’ for Merck